{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:32:26Z","timestamp":1780680746169,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00228-022-03402-2","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:37:57Z","timestamp":1666755477000},"page":"1981-1990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-1833","authenticated-orcid":false,"given":"Amandine","family":"Gouverneur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-1469","authenticated-orcid":false,"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-5483","authenticated-orcid":false,"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"3402_CR1","unstructured":"European Medicines Agency (2021) Olumiant (baricitinib) - summary of product characteristics"},{"key":"3402_CR2","unstructured":"US Food and Drug Administration (2018) Olumiant (baricitinib): highlights of prescribing information"},{"key":"3402_CR3","unstructured":"European Medicines Agency (2021) Xeljanz (tofacitinib) - summary of product characteristics"},{"key":"3402_CR4","unstructured":"US Food and Drug Administration (2020) Xeljanz (tofacitinib): highlights of prescribing information"},{"key":"3402_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/14656566.2017.1359256","volume":"18","author":"C Richez","year":"2017","unstructured":"Richez C, Truchetet M-E, Kostine M et al (2017) Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 18:1399\u20131407. https:\/\/doi.org\/10.1080\/14656566.2017.1359256","journal-title":"Expert Opin Pharmacother"},{"key":"3402_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/0008-5472.CAN-17-2291","volume":"78","author":"LJ Wilson","year":"2018","unstructured":"Wilson LJ, Linley A, Hammond DE et al (2018) New perspectives, opportunities, and challenges in exploring the human protein kinome. Cancer Res 78:15\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2291","journal-title":"Cancer Res"},{"key":"3402_CR7","unstructured":"ClinicalTrials.gov (2017) Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis"},{"key":"3402_CR8","unstructured":"European Medicines Agency (2019) Pharmacovigilance Risk Assessment Committee (PRAC) assessment report"},{"key":"3402_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"3402_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA, Piga M, Azzolin I et al (2021) Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 20:102776. https:\/\/doi.org\/10.1016\/j.autrev.2021.102776","journal-title":"Autoimmun Rev"},{"key":"3402_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.berh.2019.01.002","volume":"32","author":"JW Liew","year":"2018","unstructured":"Liew JW, Ramiro S, Gensler LS (2018) Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol 32:369\u2013389. https:\/\/doi.org\/10.1016\/j.berh.2019.01.002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3402_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.gastrohep.2020.09.002","volume":"44","author":"P Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez P, Garc\u00eda Mateo S, Quera R, Gomoll\u00f3n F (2021) Inflammatory bowel disease and the risk of cardiovascular diseases. Gastroenterol Hepatol 44:236\u2013242. https:\/\/doi.org\/10.1016\/j.gastrohep.2020.09.002","journal-title":"Gastroenterol Hepatol"},{"key":"3402_CR13","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S et al (2020) Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis 79:1400\u20131413. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761","journal-title":"Ann Rheum Dis"},{"key":"3402_CR14","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR et al (2019) cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ 71:1042\u20131055. https:\/\/doi.org\/10.1002\/art.40841","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"3402_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R et al (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26:954\u2013962. https:\/\/doi.org\/10.1002\/pds.4233","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3402_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamaophthalmol.2020.5594","volume":"139","author":"S Billioti de Gage","year":"2021","unstructured":"Billioti de Gage S, Drouin J, Desplas D et al (2021) Intravitreal anti-vascular endothelial growth factor use in France during the coronavirus disease 2019 pandemic. JAMA Ophthalmol 139:240\u2013242. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5594","journal-title":"JAMA Ophthalmol"},{"key":"3402_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jama.2017.21269","volume":"319","author":"K Bouillon","year":"2018","unstructured":"Bouillon K, Bertrand M, Bader G et al (2018) Association of hysteroscopic vs laparoscopic sterilization with procedural, gynecological, and medical outcomes. JAMA 319:375\u2013387. https:\/\/doi.org\/10.1001\/jama.2017.21269","journal-title":"JAMA"},{"key":"3402_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n37","volume":"372","author":"A Weill","year":"2021","unstructured":"Weill A, Nguyen P, Labidi M et al (2021) Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ 372:n37. https:\/\/doi.org\/10.1136\/bmj.n37","journal-title":"BMJ"},{"key":"3402_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cpt.1176","volume":"105","author":"J Bezin","year":"2019","unstructured":"Bezin J, Mansiaux Y, Noize P et al (2019) Use of lipid-lowering drugs and the risk of cataract: a population-based nested case-control study. Clin Pharmacol Ther 105:458\u2013465. https:\/\/doi.org\/10.1002\/cpt.1176","journal-title":"Clin Pharmacol Ther"},{"key":"3402_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2002","volume":"353","author":"A Weill","year":"2016","unstructured":"Weill A, Dalichampt M, Raguideau F et al (2016) Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 353:i2002. https:\/\/doi.org\/10.1136\/bmj.i2002","journal-title":"BMJ"},{"key":"3402_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1161\/STROKEAHA.119.028490","volume":"51","author":"S Maumus-Robert","year":"2020","unstructured":"Maumus-Robert S, Debette S, B\u00e9rard X et al (2020) Risk of intracranial aneurysm and dissection and fluoroquinolone use: a case-time-control study. Stroke 51:994\u2013997. https:\/\/doi.org\/10.1161\/STROKEAHA.119.028490","journal-title":"Stroke"},{"key":"3402_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen I, Douglas I, Whitaker H (2016) Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354:i4515. https:\/\/doi.org\/10.1136\/bmj.i4515","journal-title":"BMJ"},{"key":"3402_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12959-016-0078-0","volume":"14","author":"S Bou\u00e9e","year":"2016","unstructured":"Bou\u00e9e S, Emery C, Samson A et al (2016) Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J 14:4. https:\/\/doi.org\/10.1186\/s12959-016-0078-0","journal-title":"Thromb J"},{"key":"3402_CR24","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/2012.jama.11741","volume":"308","author":"ME Holmqvist","year":"2012","unstructured":"Holmqvist ME, Neovius M, Eriksson J et al (2012) Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308:1350\u20131356. https:\/\/doi.org\/10.1001\/2012.jama.11741","journal-title":"JAMA"},{"key":"3402_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/fcp.12143","volume":"29","author":"J Bezin","year":"2015","unstructured":"Bezin J, Girodet P-O, Rambelomanana S et al (2015) Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam Clin Pharmacol 29:586\u2013591. https:\/\/doi.org\/10.1111\/fcp.12143","journal-title":"Fundam Clin Pharmacol"},{"key":"3402_CR26","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/CIRCULATIONAHA.113.001874","volume":"127","author":"L Lorgis","year":"2013","unstructured":"Lorgis L, Cottenet J, Molins G et al (2013) Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation 127:1767\u20131774. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001874","journal-title":"Circulation"},{"key":"3402_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.acvd.2016.01.011","volume":"109","author":"P Tuppin","year":"2016","unstructured":"Tuppin P, Rivi\u00e8re S, Rigault A et al (2016) Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Arch Cardiovasc Dis 109:399\u2013411. https:\/\/doi.org\/10.1016\/j.acvd.2016.01.011","journal-title":"Arch Cardiovasc Dis"},{"key":"3402_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neurol.2015.06.008","volume":"172","author":"K Cosker","year":"2016","unstructured":"Cosker K, Samson S, Fagot-Campagna A et al (2016) First hospitalization for transient ischemic attack in France: characteristics, treatments and 3-year outcomes. Rev Neurol (Paris) 172:152\u2013159. https:\/\/doi.org\/10.1016\/j.neurol.2015.06.008","journal-title":"Rev Neurol (Paris)"},{"key":"3402_CR29","unstructured":"World Health Organization (WHO) Collaborating centre for drug statistics methodology. ATC\/DDD Index"},{"key":"3402_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM et al (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3402_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40744-020-00258-9","volume":"8","author":"JM \u00c1lvaro-Gracia","year":"2021","unstructured":"\u00c1lvaro-Gracia JM, Garc\u00eda-Llorente JF, Valderrama M et al (2021) Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther 8:17\u201340. https:\/\/doi.org\/10.1007\/s40744-020-00258-9","journal-title":"Rheumatol Ther"},{"key":"3402_CR32","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H et al (2019) risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ 71:1450\u20131459. https:\/\/doi.org\/10.1002\/art.40911","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"3402_CR33","doi-asserted-by":"publisher","unstructured":"Wollenhaupt J, Lee E-B, Curtis JR et al (2019) Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","DOI":"10.1186\/s13075-019-1866-2"},{"key":"3402_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"J-L Faillie","year":"2019","unstructured":"Faillie J-L (2019) Case-non-case studies: principle, methods, bias and interpretation. Therapie 74:225\u2013232. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006","journal-title":"Therapie"},{"key":"3402_CR35","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3390\/ijms22052449","volume":"22","author":"PJ Kotyla","year":"2021","unstructured":"Kotyla PJ, Engelmann M, Giemza-Stok\u0142osa J et al (2021) Thromboembolic adverse drug reactions in janus kinase (JAK) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci 22:2449. https:\/\/doi.org\/10.3390\/ijms22052449","journal-title":"Int J Mol Sci"},{"key":"3402_CR36","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/acr.23930","volume":"71","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Charles-Schoeman C, McInnes IB et al (2019) Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies. Arthritis Care Res 71:1387\u20131395. https:\/\/doi.org\/10.1002\/acr.23930","journal-title":"Arthritis Care Res"},{"key":"3402_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","volume":"43","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Curtis JR, Yun H et al (2020) An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data. Drug Saf 43:379\u2013392. https:\/\/doi.org\/10.1007\/s40264-020-00904-9","journal-title":"Drug Saf"},{"key":"3402_CR38","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","volume":"27","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Regueiro M, Yun H et al (2021) Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00ae administrative claims database with tofacitinib trial data. Inflamm Bowel Dis 27:1394\u20131408. https:\/\/doi.org\/10.1093\/ibd\/izaa289","journal-title":"Inflamm Bowel Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03402-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03402-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03402-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:04:44Z","timestamp":1668060284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03402-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03402-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the <i>Comit\u00e9 d\u2019expertise pour les recherches, les \u00e9tudes et les \u00e9valuations dans le domaine de la sant\u00e9<\/i> (CERESS) and the <i>Commission Nationale de l\u2019Informatique et des Libert\u00e9s<\/i> (CNIL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No informed consent was needed for the use of this anonymized healthcare database or anonymized pharmacovigilance database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors have completed the ICMJE uniform disclosure form at  and declare: Amandine Gouverneur, Cl\u00e9ment Prati, and Jean-Luc Cracowski no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work; no support from any organization for the submitted work; Antoine Pariente reports acting as an independent expert towards the French Medicines Agency (<i>Agence Nationale de Securit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9, ANSM<\/i>) and the European Medicines Agency (EMA). Antoine Pariente coordinates the DRUGS Systematized Assessment in real-liFe EnviRonment (DRUGS-SAFER) program funded by the <i>Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9<\/i> (ANSM); J\u00e9r\u00f4me Avouac has\/had consultancy relationship and\/or research funding in the area of potential treatments for rheumatoid arthritis from (last three years): Abbvie, Galapagos, Pfizer, Bristol Myers Squibb, Sanofi, Nordic Pharma, Chugai, and MSD; Thierry Schaeverbeke has\/had consultancy and\/or research fundings: Abbvie, Lilly, Pfizer, Galapagos, Novartis, BMS, Medac, NordicPharma, Biogen, Mylan, Janssen; Marie-Elise Truchetet has\/had consultancy relationship and\/or research funding in the area of potential treatments for rheumatoid arthritis and spondyloarthritis and their complications from (last three years): Abbvie, Galapagos, Lilly, Medac, Novartis, Pfizer, and Roche; no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}